ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Rawand Masoud
Matched on OpenAlex author ID A5112058170. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 5
- Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer. Co-author DOI 10.1038/s41389-025-00591-0↗
- Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
- Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100143↗
- Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. First author DOI 10.3390/biomedicines8080270↗
- PML hyposumoylation is responsible for the resistance of pancreatic cancer. Co-author DOI 10.1096/fj.201901091r↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alice Carrier · 5 shared papers, 2019–2025 · strength 0.75
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. DOI 10.3390/biomedicines8080270↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Gabriela Reyes‐Castellanos · 4 shared papers, 2020–2025 · strength 0.67
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. DOI 10.3390/biomedicines8080270↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Juan Iovanna · 4 shared papers, 2019–2025 · strength 0.56
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Nadine Abdel Hadi · 3 shared papers, 2020–2025 · strength 0.48
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Tristan Gicquel · 3 shared papers, 2020–2025 · strength 0.48
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Odile Gayet · 3 shared papers, 2019–2023 · strength 0.32
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Paper PML hyposumoylation is responsible for the resistance of pancreatic cancer. DOI 10.1096/fj.201901091r↗
- Nelson Dusetti · 3 shared papers, 2019–2023 · strength 0.32
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Paper PML hyposumoylation is responsible for the resistance of pancreatic cancer. DOI 10.1096/fj.201901091r↗
- Abdessamad El Kaoutari · 2 shared papers, 2020–2023 · strength 0.24
- Fabienne Guillaumond · 1 shared paper, 2023 · strength 0.15
- Mirna Swayden · 1 shared paper, 2019 · strength 0.08
- Julie Roques · 1 shared paper, 2019 · strength 0.08
- Yolande Berthois · 1 shared paper, 2019 · strength 0.08
- Philippe Soubeyran · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.